Linear Capital's Pre-A lead portfolio company **DigiSight Medical** has closed a multi-million-yuan Pre-A+ round, with existing investor Linear Capital continuing to back the company.

Recently, Hangzhou DigiSight Medical Biotechnology Co., Ltd. ("DigiSight Medical") announced the completion of a tens-of-millions-yuan Pre-A+ funding round. The round was led by the Infinity-Ophtec joint fund, with follow-on investment from New Silk Road Capital and Fangfu Venture Capital, and continued support from existing shareholders including Linear Capital. Kai Cheng Capital served as the exclusive financial advisor for this transaction. The proceeds will primarily accelerate human clinical trials for DigiSight's ophthalmic surgical robot and advance R&D for its microsurgical robot pipeline. This marks DigiSight's second funding round completed within six months, reflecting strong capital market recognition.

Founded in July 2021, DigiSight Medical is a nationally recognized technology SME. Its founding team hails from Germany's top global robotics and AI laboratories and Fortune 500 German pharmaceutical companies. To date, DigiSight has applied for and been granted multiple US and Chinese invention patents, and has won several top global and domestic competition awards.

The eye is the most delicate and complex organ in the human body. Humans derive 90% of their information through vision, and the eye stands as our most intricate organ. The fundus tissue is particularly precise, demanding surgical accuracy ideally within 10 microns. Yet the human hand exhibits natural tremors of roughly 100 microns, risking retinal damage and compromised visual recovery. Additionally, experienced ophthalmic surgeons are scarce, require exceptionally long training periods, and face immense pressure performing freehand micro-operations. DigiSight Medical's technical strengths lie in personalized physician-engineer collaboration, multi-degree-of-freedom master-slave control, and proprietary flexible structures — making it among the first teams internationally to achieve 3-micron motion precision in ophthalmic surgical robots. Its product technology and development progress are globally leading, with clinical trials imminent. Moreover, the microsurgical robot under development features nearly 20 ultra-high degrees of freedom, enabling surgeons to perform various high-difficulty, ultra-microscopic delicate operations such as anastomosis of lymphatic vessels, blood vessels, or nerves with diameters ranging from 0.3 to 0.8 millimeters — carrying significant application value across ENT, lymphatic surgery, neurosurgery, plastic surgery, and other departments.

Dr. Di Cui, CEO of DigiSight Medical, stated: "We are very pleased to announce the completion of our Pre-A+ round. This important milestone will further support our acceleration of microsurgical robot technology development and clinical application. We thank Infinity Capital and the Ophtec joint fund, New Silk Road Capital, and Fangfu Venture Capital for their support and confidence, and our existing shareholders including Linear Capital for their continued commitment. We also thank the Hangzhou and Shangcheng district governments for their ongoing care and support, and our partner Kai Cheng Capital for their assistance. This round demonstrates the market's strong confidence in DigiSight and further validates our leading position in the microsurgical robot field. We will remain focused on continuous innovation in robotic micro-manipulation technology, developing and delivering high-precision, high-dexterity, high-stability robotic micro-manipulation platforms that enable physicians to achieve fine, quantified, and visualized operations in delicate tissues and complex surgeries — bringing breakthrough technological innovation to ophthalmology and ultra-microsurgery."

Zhang Shuai, project lead at Infinity Capital, commented: "Fundus diseases represent substantial unmet needs, and fundus surgeons urgently need supporting equipment to assist with high-difficulty procedures. DigiSight Medical astutely identified fundus disease as its entry point, focusing on ultra-microsurgical solutions and steadfastly proceeding from clinical needs to creatively develop self-designed solutions addressing frontline physicians' pain points. We see in the DigiSight team, led by Dr. Di Cui, resolute and efficient execution capability alongside precious entrepreneurial conviction — creating a classic case of innovative medical device 'physician-engineer collaboration.' Infinity has long positioned in the ophthalmology track, and we are very pleased to accompany DigiSight Medical. We greatly anticipate DigiSight becoming an indispensable contributor in ophthalmology and even ultra-microsurgical treatment."

Zhao Chunsheng, managing partner of Hefei Kangshi Partnership Enterprise, stated: "Once DigiSight Medical's products under development reach market, they can substantially improve success rates for fundus and retinal surgeries while lowering the operational threshold for ophthalmic surgeons — benefiting more physicians and patients. Meanwhile, as a leading enterprise in the ophthalmology industry, Ophtec is comprehensively building out its OPHTEC ophthalmic medical service chain system and ecosystem. We believe DigiSight Medical will have abundant collaboration opportunities with Ophtec and its invested or controlled enterprises."

New Silk Road Capital commented: "The surgical robotics field has always been a key investment focus for us. In recent years we have successively invested in multiple outstanding surgical robotics companies across different vertical segments. As China's aging population intensifies, ophthalmic diseases — particularly age-related degenerative ocular conditions — are increasingly prevalent. On this foundation, we are quite optimistic about new opportunities for surgical robotics applied in ophthalmology. DigiSight Medical's advanced technology and products show us future potential to provide more effective solutions for more patients troubled by difficult diseases in ophthalmology, while adding more possibilities for ophthalmic surgeons on the path of precision medicine. We firmly believe DigiSight Medical can grow into a leading enterprise in domestic and even global markets for ophthalmic and microsurgical robotics, benefiting more patients in clinical use."

Fangfu Venture Capital stated: "The physician-engineer collaboration domain represented by intelligent surgical robots is one of Fangfu Venture Capital's key focus and investment areas. DigiSight Medical's self-developed microsurgical robot can improve micro-manipulation precision, break through physicians' physiological operational limits, and effectively address clinical pain points — with substantial future application space. DigiSight Medical's founding team has years of accumulated expertise in surgical robot micro-manipulation, particularly with industry-leading advantages in ophthalmic microsurgical robot products. Fangfu Venture Capital is optimistic about DigiSight Medical's development potential and will leverage its own resources and experience to support the company, looking forward to long-term cooperation."

Zou Guowen, founding partner of Kai Cheng Capital, said: "Kai Cheng Capital is honored to serve as exclusive financial advisor for DigiSight Medical's Pre-A+ round. DigiSight Medical uses ophthalmology as its entry point, extending high-precision ultra-microsurgical manipulation underlying technology to microsurgical applications — breaking through human physiological operational limits and assisting physicians in completing ultra-high-difficulty surgeries. The clinical demand is extremely strong, with enormous market potential. We have full confidence that DigiSight Medical will become a leading enterprise in the ophthalmic and microsurgical robotics track."

About Linear Capital

We are hiring for our investment team. Multiple positions are currently open — please click here for details.

Linear Capital is an early-stage investment firm focused on "frontier technology + industry" — frontier technologies represented by data intelligence, digital new infrastructure, next-generation robotics, and new technological transformations in traditional domains (such as biomedicine, materials, energy), applied across vertical industries to substantially improve industrial efficiency, empower solutions to pain points, and complete industrial upgrading — achieving excess commercial returns through substantial increases in industrial value. The firm currently manages ten funds with total AUM of approximately $2 billion.

Our investment stage focuses on leading angel to Series A rounds, with typical check sizes of $3–8 million or RMB equivalent.

We have made early-stage investments in over 120 entrepreneurial teams including Horizon Robotics, Kujiale, Sensors Data, Tezign, Rokid, Guandata, and Agile Robots. The combined valuation of Linear's portfolio companies is approximately $20 billion.

In the near term, Linear Capital is working to become the premier "Data Intelligence Technology Fund," with a long-term vision of gradually building the most influential "Frontier Technology Application Fund."